NCT05056246View on ClinicalTrials.gov

Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

April 8, 2022

Study Completion Date

April 8, 2022

Conditions

Healthy Participants

Interventions

DRUG

AMG 133

Solution for SC injection

Trial Locations (1)

90630-4738

WCCT Global LLC, Cypress

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY